Associations - CDKN2A mutation

CDKN2A mutation CDKN2A mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	CDKN2A mutation CDKN2A mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials	atezolizumab Sensitive: B - Late Trials
CDKN2A mutation CDKN2A mutation	Breast Cancer Breast Cancer	CDKN2A mutation CDKN2A mutation	Breast Cancer Breast Cancer	ribociclib Resistant: B - Late Trials	ribociclib Resistant: B - Late Trials
CDKN2A mutation CDKN2A mutation	Gallbladder Cancer Gallbladder Cancer	CDKN2A mutation CDKN2A mutation	Gallbladder Cancer Gallbladder Cancer	palbociclib Resistant: C3 – Early Trials	palbociclib Resistant: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	CDKN2A mutation CDKN2A mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	palbociclib Sensitive: C3 – Early Trials	palbociclib Sensitive: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Pancreatic Cancer Pancreatic Cancer	CDKN2A mutation CDKN2A mutation	Pancreatic Cancer Pancreatic Cancer	palbociclib Resistant: C3 – Early Trials	palbociclib Resistant: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Solid Tumor Solid Tumor	CDKN2A mutation CDKN2A mutation	Solid Tumor Solid Tumor	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Melanoma Melanoma	CDKN2A mutation CDKN2A mutation	Melanoma Melanoma	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Urothelial Cancer Urothelial Cancer	CDKN2A mutation CDKN2A mutation	Urothelial Cancer Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Biliary Tract Cancer Biliary Tract Cancer	CDKN2A mutation CDKN2A mutation	Biliary Tract Cancer Biliary Tract Cancer	toripalimab Resistant: C3 – Early Trials	toripalimab Resistant: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Non Small Cell Lung Cancer NSCLC	CDKN2A mutation CDKN2A mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Penile Cancer Penile Cancer	CDKN2A mutation CDKN2A mutation	Penile Cancer Penile Cancer	nivolumab Sensitive: C4 – Case Studies	nivolumab Sensitive: C4 – Case Studies
CDKN2A mutation CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	CDKN2A mutation CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	AZD1775 + VIC-1911 Sensitive: D – Preclinical	AZD1775 + VIC-1911 Sensitive: D – Preclinical
CDKN2A mutation CDKN2A mutation	Non Small Cell Lung Cancer NSCLC	CDKN2A mutation CDKN2A mutation	Non Small Cell Lung Cancer NSCLC	AZD1775 + VIC-1911 Sensitive: D – Preclinical	AZD1775 + VIC-1911 Sensitive: D – Preclinical
CDKN2A mutation CDKN2A mutation	Melanoma Melanoma	CDKN2A mutation CDKN2A mutation	Melanoma Melanoma	palbociclib Sensitive: D – Preclinical	palbociclib Sensitive: D – Preclinical